促红素与癌症化疗患者生活质量及疗效的相关性研究

Clinical observation of correlation between rhuEPO and quality of life and the efficacy of chemotherapy in anemic cancer patients undergoing chemotherapy

目的观察促红素与癌症化疗患者生活质量及疗效的相关性。方法88例患者随机分为治疗组及对照组。治疗组化疗同时给rHuEPO10000U皮下注射,每周3次,连续4周。对照组单纯化疗,不用rHuEPO。结果治疗组血红蛋白(Hb)升高20g/L者占44.4%(20/45),而对照组仅为4.7%(2/43),两组差异有显著性(P=0.000098)。治疗组Karnofsky评分升高20分以上者占40.0%(18/45),对照组占18.6%(8/43,P=0.0279)。生活质量SF-36表显示,治疗组在治疗前后PF、RP、VT、MH、BP方面差异有显著性(P<0.05)。亚组分析:治疗组分为Hb升高20g/L以上及不足20g/L组,发现Hb升高20g/L以上组PF、VT、RP、MH方面分数明显提高,且差异更显著。治疗组和对照组化疗有效率分别为48.5%(16/33)及46.7%(14/30),差异无显著性。结论rHuEPO可以改善中国癌症患者的贫血及改善癌症患者的生活质量,生活质量的改善可通过改善贫血实现。

Objective To observe correlatoin between rHuEPO and quality of life and the efficacy of chemotherapy in anemic cancer patients undergoing chemotherapy. Methods The 88 patients were divided into two groups ,chemotherapy combined with rHuEPO group 45 cases （rHuEPO 10000 units 3 times per week for 4 weeks） and single chemotherapy group 43 cases. Results The cases with increase in Hb by more than 20 g/L accounted for 44.4% （20/45） in chemotherapy combined with rHuEPO group and 4.7% （ 2/ 43 ）in single chemotherapy group ,P =0.000098. The cases with increase in KPS more than 20 accounted for 40.0% （18/45）in chemotherapy combined with rHuEPO group and 18.6% （8/43）in single chemotherapy group, P = 0.0279. PF, RP, VT, MH, BP of SF-36 were increased signifcantly in chemotherapy combined with rHuEPO group （P 〈 0. 05）. The 45 cases of chemotherapy combined with rHuEPO group were divided into increase in by Hb more than 20 g/L group and increase in by Hb less than 20 g/L group. PF,RP,VT,MH of SF-36 were increased more significantly in increase in by Hb more than 20 g/L group. The response rates （RR） of chemotherapy in the two groups were 48.5% （16/33） and 46.7% （14/30） respectively. Conclusions rHuEPO can improve the level of hemoglobin significantly in anemic cancer patients and improve the quality of life. There is no correlatoin between rHuEPO and chemotherapy.